Dan Kirby

Corporate Officer/Principal at IOVANCE BIOTHERAPEUTICS, INC.

Net worth: 611 295 $ as of 30/06/2026

54 year

Health Technology

Profile

Dan Kirby currently works at Iovance Biotherapeutics, Inc., as Chief Commercial Officer from 2025.
Mr. Kirby also formerly worked at Bristol Myers Squibb Co., as Vice President & Head-US Cell in 2018, Omeros Corp., as Chief Commercial Officer from 2018 to 2020, and Orca Biosystems, Inc., as Chief Commercial Officer.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
IOVANCE BIOTHERAPEUTICS INC 0.03%	11/05/2026	146,946 ( 0.03% )	611 295 $	30/06/2026

Dan Kirby active positions

Companies	Position	Start
IOVANCE BIOTHERAPEUTICS, INC.	Corporate Officer/Principal	10/02/2025

All active positions of Dan Kirby

Former positions of Dan Kirby

Companies	Position	End
OMEROS CORPORATION	Corporate Officer/Principal	01/01/2020
BRISTOL-MYERS SQUIBB COMPANY	Corporate Officer/Principal	01/09/2018
Orca Biosystems, Inc. Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers	Corporate Officer/Principal	-

See the detail of Dan Kirby's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dan Kirby's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Bristol Myers Squibb Co. Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products	Health Technology
Omeros Corp. Omeros Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes small-molecule & protein therapeutics	Health Technology
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer	Health Technology
Orca Biosystems, Inc. Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers	Health Technology